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PCV9
PROPHYLAXIS AGAINST DEEP-VEIN 
THROMBOSIS AND FATAL PULMONARY 
EMBOLISM IN KNEE ARTHROPLASTIES:
A COST-EFFECTIVENESS STUDY
Nerurkar J, Wade WE, Martin BC
The University of Georgia College of Pharmacy, Athens, GA, USA
OBJECTIVE: This study seeks to determine the costs and
effectiveness of warfarin, ardeparin, enoxaparin, and no-
prophylaxis for patients undergoing knee arthroplasty.
METHODS: A decision-analytic model was developed
using TreeAge software to compare the three treatment
strategies and a no-prophylaxis option. The effectiveness
measure was deaths prevented for a simulated cohort of
10,000 patients undergoing knee arthroplasty. Costs were
valued in U.S. dollars using a payer’s perspective and
costs and probabilities of events were obtained from the
published literature. RESULTS: All three treatment strat-
egies were cost saving and more effective than the no pro-
phylaxis option. Enoxaparin had the lowest expected
cost of $3,242 per patient and prevented 198 deaths for
the cohort of 10,000 persons. Warfarin was dominated
by enoxaparin and ardeparin was the most effective op-
tion and had a marginal cost-effectiveness ratio of $207,342
per death avoided. Results of the sensitivity analysis will
be presented. CONCLUSION: All three treatments are
cost saving and more effective than no prophylaxis indi-
cating that prophylaxis is preferred to the do nothing
strategy. Warfarin was dominated by enoxaparin and
should not be considered a first line anticoagulant to pre-
vent DVT in this patient population. Ardeparin was the
most effective option that had a marginal cost-effective-
ness ratio above many societal willingness to pay thresh-
olds and may not be considered a desirable use of health
care resources. The robustness of these findings will be
explored using sensitivity analysis.
PCV10
RETROSPECTIVE MEDICAL RECORD REVIEW 
TO DETERMINE THE “AT GOAL” PATIENTS 
WITH HYPERTENSION AND/OR DYSLIPIDEMIA
Gunnarsson P1, Livengood K2, Lytken Larsen M3, Pettersson 
S4, Claeys MJ5, Norstrom F6, Saldeen Nilehn K7, Beys J8
1Outcomes Research Department, Pfizer European Service 
Center, Zaventem, Belgium; 2Outcomes Research Department, 
Pfizer Pharmaceutical Group, New York, NY, USA; 3University 
Department of Cardiology, Aarhus Amtsygehus, Aarhus, 
Denmark; 4Specialist Enheten Proxima, Nacka Sjukhus, Nacka, 
Sweden; 5Department of Cardiology, U.Z. Antwerpen, Edegem, 
Belgium; 6Medicinkliniken, Angelholms Sjukhus, Angelholm, 
Sweden; 7Department of Internal Medicine, Sahlgrenska University 
Hospital, Gothenburg, Sweden; 8St. Maarten Ziekenhuis,
Duffel, Belgium
OBJECTIVE: To generate data about treatment patterns
for patients with hypertension and/or dyslipidemia and
to identify the number achieving a treatment goal accord-
ing to international guidelines. The data collected will
also be used to validate a new software program that the
Outcomes Research department at Pfizer has developed.
METHODS: Six clinics/doctors in three European coun-
tries (Belgium, Denmark, and Sweden) participated in
this retrospective medical record review. For each patient
visit, the available data from the previous 1–2 years was
collected. Data collected included blood pressure mea-
surements, lipid profiles, glucose levels, HbA1c, co-mor-
bidities, and medications. Guidelines used in the analysis
were: Hypertension—1999 WHO-ISH guidelines for the
management of hypertension; Hyperlipidemia—Recom-
mendations of the Second Joint Task Force of European
and other Societies on Coronary Prevention. RESULTS:
Reviewing each patient’s last visit, 33 of 189 were at goal
for hypertension or 17%. For lipids, 42 of 179 (32%)
were at goal. 50% of patients diagnosed with diabetes
had HbA1c below 7% at the last visit and 65% of them
were at goal for lipids, but only 14% for hypertension.
CONCLUSION: The number of patients found to be “at
goal” in this study is far from being optimal, but it is sim-
ilar to numbers seen in the literature. The software was
found to function as expected by utilizing only the data
that doctors routinely collect in their practice. The “at
goal” information is valuable, because it allows health
care providers to track over time one of the factor’s that
will be (and is being) used to measure the quality of the
care they are providing. HMOs in the US can use the in-
formation gathered to create reports for NCQA and HE-
DIS and in the UK the new cardiovascular NSF standards
have been incorporated into the software.
PCV11
DETERMINANTS OF COSTS AND RESOURCE 
UTILIZATION ASSOCIATED WITH OPEN 
HEART SURGERY
Sokolovic E1, Schmidlin D2, Schmid E2, Ruef C3, Szucs T1
1Department of Medical Economics, University Hospital, 
Zurich, Switzerland; 2Institute for Anesthesiology, University 
Hospital, Zurich, Switzerland; 3Department of Hospital 
Hygiene, University Hospital, Zurich, Switzerland
OBJECTIVE: This study sought to determine the corre-
lates of in-hospital costs for patients undergoing open-
heart surgery at the 962 bed University Hospital in Zurich.
METHODS: We performed a retrospective analysis of all
heart surgery patients referred to University Hospital who
were covered by a fixed fee (29 500 SFr) arrangement in
1998, except those who had heart transplantation. We an-
alyzed the prospectively evaluated preoperative (age, BMI,
clinical characteristics, preoperative scores, history of pre-
vious heart surgery), intraoperative (operation time,
anesthesia time, extracorporal circulation time, intubation
hours) respectively postoperative (APACHE II, SAPS II
Scores, infection, rethoracotomy) factors. RESULTS: In
total 242 patients were hospitalized in 1998 under this
fixed fee arrangement. The treatment of 69 patients (29%)
caused costs higher than 40 000 SFr. Median cost per pa-
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tient was 33 000 SFr (interquartile range 27211–43476).
Median age of the patients was 63 years (interquartile
range 55–70). We found that the following preoperative
characteristics were significantly associated with cost: age
(P  0.001), preoperative cardiac diagnosis (P  0.001),
preoperative risk scores (P  0.0001). The bivariate analy-
sis showed a highly significant correlation between intra-
operative variables, except aorta clamp time (P  0.0001).
All postoperative variables turned out to be significantly
predictive of costs (P  0.0001). In order to predict the
costs we developed a linear model based on significant pre-,
intra- and postoperative variables. The model predicted
hospital costs (Y) for patients based on EuroSCORE (X1),
operation time (X2), intubation time (X3) and postoper-
ative infection (X4). Median length of stay was 10 days
(interquartile range 8–12) in the general ward and 1 day
(interquartile range 1–3) in the intensive care unit. CON-
CLUSIONS: Hospital costs are closely related to the pre-
operative risk scores, intraoperative variables and occur-
rence of postoperative complications, which means that
this model can prospectively identify patients at the first
postoperative day, who are at risk for excess of costs.
PCV12
A COST COMPARISON STUDY OF AMLODIPINE 
AND ENALAPRIL IN THE TREATMENT OF 
HYPERTENSION IN EUROPE
Doyle J1,2, Arikian S1,2, Casciano J1, Casciano R1, Gonzalez M1, 
Kopp Z3
1The Analytica Group, New York, NY, USA; 2Columbia 
University, School of Public Health, New York, NY, USA; 
3Pfizer, New York, NY, USA
OBJECTIVES: To compare the treatment costs of amlo-
dipine versus enalapril in the treatment of mild to moder-
ate hypertension in France, Italy, Germany, Spain and
Sweden. METHODS: A post-hoc analysis was performed
by examining the patient-level data from a one year, dou-
ble blind clinical trial of amlodipine (n  231) versus
enalapril (n  230). We determined the frequency and
dosage of antihypertensives administered longitudinally
in both treatment arms. The analysis also compared the
adverse event profiles and efficacy rates in each treatment
group. Ex-factory costs of amlodipine, enalapril, and the
diuretic, hydrochlorothiazide (HCTZ), were obtained for
all countries. The net costs of treatment were calculated
within trial phases and throughout the 50-week trial pe-
riod. RESULTS: In all the countries evaluated, the aver-
age treatment costs in the amlodipine group were less ex-
pensive than those in the enalapril group producing a
cost savings over the trial duration ranging from 2%
($2.81) in Spain to 32% ($81) in France. The mean final
visit drug dosages per patient were 7.2 mg/day for amlo-
dipine and 28 mg/day for enalapril. The total reduction
in sitting DBP was not significantly different between
treatment groups; however, significantly more patients (P 
0.05) in the enalapril group (n  46, 20%) required the
use of HCTZ to attain control of DBP than in the amlo-
dipine group (n  27, 11.7%). Finally, there were no sig-
nificant differences (P  0.05) in adverse events between
groups. CONCLUSION: Healthcare providers should favor
utilization of amlodipine over enalapril as a less expen-
sive and equally effective means of achieving blood pres-
sure control in the mild to moderate hypertensive popula-
tions of Europe.
PCV13
COSTS ASSOCIATED WITH HEALTH SERVICES 
UTILIZATION IN PATIENTS WITH
VARICOSE VEINS
Kurz X1, Durand-Zaleski2, Abenhaim L3 for the VEINES
Study Group
1Laboratory of Pharmacology, University of Liege, Liege, 
Belgium; 2Department of Public Health, Henri Mondor 
Hospital, Creteil, France; 3Centre for Clinical Epidemiology and 
Community Studies, Jewish General Hospital, McGill University, 
Montreal, QC, Canada
OBJECTIVE: To assess direct medical costs in patients
with varicose veins (VV) and the association between VV
and costs in patients with venous disorders. METHODS:
416 patients included in the VEINES cohort study in Bel-
gium were followed for a mean of 11.34 months, with
health service utilization measured three times from phy-
sicians and patients. Items measured included consulta-
tions to physicians and health professionals, diagnostic tests,
drugs, compression material and interventions (sclero-
therapy, surgery, wound care, physiotherapy). Total costs
(T) and costs for patients (P) were valued. RESULTS:
Age and gender-standardized one-year adjusted mean
costs for all patients with VV were US$311.24 (T) and
$107.36 (P). Interventions represented 46.2% of T costs
and 14.5% of P costs, whereas drug costs represented
17.1% and 22.6% respectively. In patients without VV
(only symptoms or telangiectasia), T and P costs were
US$134.72 and $75.67. Costs in patients with VV alone
were US$304.9 (T) and $81.8 (P). Patients with VV and
ulcer had the lowest costs (T: 189.1, P: 111.2) due to the
small number of surgical interventions. In semilog covari-
ance model adjusted for other venous disorders and de-
terminants of health service utilization in all patients with
venous disorders, a cost ratio (CR) of 2.32 (95% CI: 1.25
to 4.30) was observed for patients with VV vs. without
VV. Other main cost determinant was baseline measure
of disease-specific quality of life (VEINES-QOL) with in-
verse relationship (CR for highest vs. lowest QoL scores:
0.14, 95% CI: 0.07–0.27). CONCLUSIONS: Costly in-
terventions (e.g. surgery) are predominantly used by pa-
tients with VV alone for cosmetic reason, and with VV
and skin changes possibly for ulcer prevention. Disease-
specific QoL (VEINES-QOL) could be an important out-
come in baseline evaluation of clinical and pharmacoeco-
nomic studies on VV, as it was associated with level of
health services utilization over 12 months.
